Shire to acquire NPS Pharmaceuticals for $5.2 billion

DUBLIN — Shire and NPS Pharmaceuticals on Sunday announced that the companies have entered into a merger agreement where Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 billion. 

 

Shire plans to accelerate the growth of NPS Pharma’s portfolio through its market expertise in gastrointestinal disorders, core capabilities in rare disease patient management and global footprint. The transaction has been approved unanimously by the boards of directors of both Shire and NPS Pharma.

 

NPS Pharma is a rare disease-focused biopharmaceutical company and its first product, Gattex/Revestive (teduglutide [rDNA origin]) for injection, is approved in the United States and Europe to treat adults with short bowel syndrome who are dependent on parenteral support. NPS Pharma also has a registration phase product, Natpara/Natpar (rhPTH -83) for the treatment of hypoparathyroidism.

 

“The acquisition of NPS Pharma is a significant step in advancing Shire’s strategy to become a leading biotechnology company," said Flemming Ornskov, Shire CEO. "With our global strength and expertise in both rare diseases and GI, Shire is uniquely positioned to drive the continued success of Gattex/Revestive, and, if approved, commercialize NPS Pharma’s pipeline compound Natpara/Natpar.